The authors observed that CDK4/6 (palbociclib) and CDK1 (RO-3306) inhibitors led to a reduction in cell proliferation in tumors induced with BE(2)C and SK-N-AS lines (by Ki67 marker analysis); treatment was administered on days 11 and 13 after tumor induction). The gene discussed is CDK1; the disease is neoplasm.